投与量と反応関係: 選択性と特異性

Drug selectivity describes a drug's strong preference for its intended receptor over other receptors in the body. Drug specificity refers to a drug's ability to interact with only a specific target, producing the desired therapeutic effect without causing unintended physiological changes. High specificity ensures targeted action with minimal side effects, while selectivity determines which receptor among many similar ones the drug preferentially binds.

Salbutamol is a selective beta-2 adrenergic agonist with high affinity for beta-2 receptors in bronchial smooth muscle, causing bronchodilation without affecting the heart. Isoprenaline, a nonselective beta agonist, stimulates both beta-1 receptors in the heart and beta-2 receptors in the bronchioles, increasing heart rate alongside bronchial relaxation. Salbutamol's selectivity makes it safer and more effective for asthma treatment.

Omeprazole, a proton-pump inhibitor, exhibits high specificity by selectively inhibiting the proton pump in parietal cells of the stomach, decreasing acid secretion into the stomach lumen. Its targeted interaction with this specific enzyme produces the desired therapeutic effect without impacting other physiological processes. This high specificity results in minimal off-target interactions and fewer adverse effects.

Off-target interactions occur when drugs bind to unintended receptors, enzymes, or ion channels throughout the body. Low-specificity drugs like amiodarone interact with multiple targets beyond their primary action, leading to several adverse effects. These unintended interactions result from weak drug-receptor selectivity, causing the drug to bind to similar molecular structures across different tissues and systems.

Different types of receptors are expressed throughout the body, and drugs interact with these receptors based on their selectivity and affinity. A selective drug preferentially binds to its intended receptor type over structurally similar receptors in other tissues. For example, selective beta-2 agonists target bronchial receptors while avoiding cardiac beta-1 receptors, allowing drugs to produce localized therapeutic effects while minimizing systemic side effects.

Amiodarone demonstrates low specificity by affecting multiple ion channels throughout the body, not just those involved in cardiac rhythm regulation. This broad interaction profile causes various side effects beyond its intended antiarrhythmic action. The drug's weak selectivity for specific ion channels means it produces unintended physiological changes in multiple organ systems, limiting its therapeutic window and increasing adverse effect risk.

Receptor affinity determines how strongly a drug binds to a specific receptor compared to other receptors. High affinity for the intended receptor combined with low affinity for off-target receptors creates selectivity. Salbutamol's high affinity for beta-2 receptors versus beta-1 receptors exemplifies this principle, allowing the drug to preferentially activate bronchial smooth muscle while minimizing cardiac effects.